公开(公告)号：US20240024275A1

公开(公告)日：2024-01-25

申请号：US18144890

申请日：2023-05-09

Applicant: Alkermes Pharma Ireland Limited

Inventor： Tarek A. Zeidan ,  Scott Duncan ,  Christopher P. Hencken ,  Thomas Andrew Wynn ,  Carlos N. Sanrame

IPC: C07C233/90

CPC classification number: C07C233/90

Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

公开(公告)号：US10973816B2

公开(公告)日：2021-04-13

申请号：US16595608

申请日：2019-10-08

Applicant: ALKERMES PHARMA IRELAND LIMITED

Inventor： Wilfredo Morales ,  Tarek A. Zeidan ,  Renato A. Chiarella ,  Steven G. Wright ,  Jason M. Perry

IPC: A61K31/496 ,  A61K31/00 ,  C07D401/12

Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.

公开(公告)号：US10954250B2

公开(公告)日：2021-03-23

申请号：US14612853

申请日：2015-02-03

Applicant: Alkermes Pharma Ireland Limited

Inventor： Laura Cook Blumberg ,  John A. Lowe, III ,  Orn Almarsson ,  Juan Alvarez ,  Tarek A. Zeidan

IPC: C07D495/04 ,  A61K47/54

Abstract: The present invention relates to compounds of Formula I:

公开(公告)号：US20190367501A1

公开(公告)日：2019-12-05

申请号：US16540802

申请日：2019-08-14

Applicant: ALKERMES PHARMA IRELAND LIMITED

Inventor： Laura Cook Blumberg ,  Julius F. Remenar ,  Orn Almarsson ,  Tarek A. Zeidan

IPC: C07D417/12 ,  C07F9/6558 ,  C07D215/14 ,  C07D263/58 ,  C07D215/00 ,  C07D215/22 ,  C07D471/04 ,  C07D471/14 ,  C07H19/06 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D239/553 ,  C07D239/56

Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

公开(公告)号：US10428058B2

公开(公告)日：2019-10-01

申请号：US16023887

申请日：2018-06-29

Applicant: ALKERMES PHARMA IRELAND LIMITED

Inventor： Laura Cook Blumberg ,  Julius F. Remenar ,  Orn Almarsson ,  Tarek A. Zeidan

IPC: C07D417/12 ,  C07F9/6558 ,  C07D215/14 ,  C07D263/58 ,  C07D215/00 ,  C07D215/22 ,  C07D471/04 ,  C07D471/14 ,  C07H19/06 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D239/553 ,  C07D239/56

Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

公开(公告)号：US10351529B2

公开(公告)日：2019-07-16

申请号：US16131773

申请日：2018-09-14

Applicant: Alkermes Pharma Ireland Limited

Inventor： Julius F. Remenar ,  Laura Cook Blumberg ,  Tarek A. Zeidan

IPC: C07D401/12 ,  C07D215/227 ,  C07F9/6558 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D401/14 ,  C07D215/22 ,  A61K31/496 ,  C07D471/04 ,  C07D417/12 ,  C07D263/58 ,  A61K31/497 ,  C07D241/04

Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

公开(公告)号：US20190201367A1

公开(公告)日：2019-07-04

申请号：US16145703

申请日：2018-09-28

Applicant: Alkermes Pharma Ireland Limited

Inventor： Tarek A. Zeidan ,  Scott Duncan ,  Christopher P. Hencken ,  Thomas Andrew Wynn ,  Carlos N. Sanrame

IPC: A61K31/225 ,  C07D491/113 ,  C07D211/06 ,  C07D207/40 ,  C07D295/088 ,  C07D211/38 ,  C07C317/28 ,  C07C317/18 ,  C07D207/06 ,  C07C233/91 ,  C07C233/18 ,  C07C229/16 ,  C07C219/08 ,  C07D209/52

CPC classification number: A61K31/225 ,  C07C219/08 ,  C07C229/16 ,  C07C233/18 ,  C07C233/91 ,  C07C317/18 ,  C07C317/28 ,  C07D207/06 ,  C07D207/40 ,  C07D209/52 ,  C07D211/06 ,  C07D211/38 ,  C07D295/088 ,  C07D491/113

Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

公开(公告)号：US20190084937A1

公开(公告)日：2019-03-21

申请号：US16131773

申请日：2018-09-14

Applicant: Alkermes Pharma Ireland Limited

Inventor： Julius F. Remenar ,  Laura Cook Blumberg ,  Tarek A. Zeidan

IPC: C07D215/227 ,  A61K31/497 ,  C07D263/58 ,  C07D401/12 ,  C07D417/12 ,  C07D471/04 ,  C07F9/6558 ,  A61K31/496 ,  C07D215/22 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D241/04

CPC classification number: C07D215/227 ,  A61K31/496 ,  A61K31/497 ,  C07D215/22 ,  C07D241/04 ,  C07D263/58 ,  C07D401/12 ,  C07D401/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6558 ,  C07F9/65583

Abstract: Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

公开(公告)号：US20190031648A1

公开(公告)日：2019-01-31

申请号：US16023887

申请日：2018-06-29

Applicant: ALKERMES PHARMA IRELAND LIMITED

Inventor： Laura Cook Blumberg ,  Julius F. Remenar ,  Orn Almarsson ,  Tarek A. Zeidan

IPC: A61K31/496 ,  C07F9/6558 ,  C07D215/14 ,  C07D263/58 ,  C07D215/00 ,  C07D215/22 ,  C07D417/12 ,  C07D239/56 ,  C07D471/14 ,  C07H19/06 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D239/553 ,  C07D471/04

Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

公开(公告)号：US20190015408A1

公开(公告)日：2019-01-17

申请号：US16043721

申请日：2018-07-24

Applicant: ALKERMES PHARMA IRELAND LIMITED

Inventor： Wilfredo Morales, JR. ,  Tarek A. Zeidan ,  Renato A. Chiarella ,  Steven G. Wright ,  Jason M. Perry

IPC: A61K31/496 ,  C07D401/12 ,  A61K31/00

Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.